Michael A. Postow, MD

People with cancer have more treatment opportunities than ever before, but I believe we can do even better. My research focuses on improving immunotherapy and targeted therapy for patients with melanoma and other cancers. I am honored that my research efforts as part of a team to develop the combination of nivolumab (Opdivo®) and ipilimumab (Yervoy®) led to FDA approval in 2015 and were subsequently selected by the American Society of Clinical Oncology as a major scientific advance in melanoma care. I am grateful for opportunities to travel around the world to share the results of these advances with other medical oncologists, scientists, and patients as well as having received research awards from the Society for Immunotherapy of Cancer and the American Society of Clinical Oncology. I am also excited about having published a handbook on all aspects of oncology care, called Pocket Oncology.   

I strongly believe in the importance of creating a close, trusting relationship with each patient and family as we work together for the best treatment plan possible.